Skip to main content

Bioceres Crop Solutions Corp.

corporate_fare Company Profile

Bioceres Crop Solutions Corp.

BIOX·NASDAQ·Industrial Applications And Services·CIK 0001769484

The company operates in three segments: crop protection, seed and integrated products, and crop nutrition. Its research and development facilities are located in Pergamino, Argentina; Davis, California; and Helsinki, Finland. The company also maintains sales offices or subsidiaries in 11 countries: Argentina, Brazil, Bolivia, Colombia, Estonia, France, Paraguay, Russia, South Africa, United States, and Uruguay. As of June 30, 2025, the company had 751 full-time employees globally. In the Crop Protection segment, key products include adjuvants and pest control molecules. Adjuvants are high-tech molecules used in tank mixes to improve the application and effectiveness of active ingredients like herbicides, insecticides, and fungicides, resulting in better spraying performance, reduced usage rates, and lower residue levels. This segment generated US$181.9 million in revenue with a 38% Gross Margin for the year ended June 30, 2025. Growth drivers include the penetration of the bioprotection portfolio into mainstream row crop agriculture, adjuvant expansion in Brazil and Paraguay, expanding installed capacity utilization (particularly in Brazil), and new registration approvals. Commercial partners include Corteva, Syngenta, DOW, Nufarm, Yara, Croda, Zschimmer & Schwarz, and Momentive. The Seed & Integrated Products segment offers seed treatment packs, seed traits, and seed germplasm. This segment recorded US$63.7 million in revenue with a 30% Gross Margin for the year ended June 30, 2025. Key growth drivers include the commercialization of HB4 technology. Commercial partners include Florimond Desprez, Corteva, GDM Seeds, Syngenta, and TMG. The Crop Nutrition segment provides micro-bead fertilizers, inoculants, biofertilizers, crop health products, and biostimulants. This segment generated US$89.5 million in revenue with a 48% Gross Margin for the year ended June 30, 2025. International expansion of bionutrition sales is a key growth driver. Commercial partners include De Sangosse, Syngenta, Valent BioSciences, Corteva, Biowish, Spraytec, and Stoller.

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors BIOX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Major Shareholder Continues Selling, Reduces Stake to 6.89%
  • Bioceres Subsidiary Rizobacter Completes $42.7M Debt Exchange Offer Amid Financial Distress
  • Bioceres Reports $10M Net Loss, Negative EBITDA Amid Revenue Decline and Ongoing Debt Issues
  • Bioceres Q3 Revenue Plunges 23%, Posts $10M Loss; Foreclosure Adds to Woes
  • EU Withdraws Soymeal with Bioceres' HB4 GMO Strain Over Regulatory Breach

Financial Snapshot

Fiscal year ended June 30, 2025
Revenue
$335.11M
Net Income
-$58.85M
Diluted EPS
-$0.88
Op. Cash Flow
$49.91M
Free Cash Flow
$44.26M
Gross Profit
$131.68M
Operating Income
-$2.24M
Cash & Equivalents
$19.49M
Total Debt
$38.2M
Debt / Equity
0.13×
Net Margin
-17.6%
Source: 20-F · filed 2025-11-10 · accession 0001104659-25-108999

Insider Transactions

BIOX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with B →
$0.42
52-week range · as of 2026-06-01 $0.3472 – $5.16
Market cap
$26.56M
Volume
109.4K (0.4× avg)
3-mo avg 295.1K
Live data · 2026-06-14 03:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BIOX - Latest Insights

BIOX
Jun 01, 2026, 5:16 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.4837
Real-time Price: $0.420 info
Change: -$0.0637 (-13%) info
Market Cap: $26.556M info
BIOX
Jun 01, 2026, 10:16 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.4338
Real-time Price: $0.420 info
Change: -$0.0138 (-3%) info
Market Cap: $26.556M info
BIOX
May 12, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.451
Real-time Price: $0.420 info
Change: -$0.031 (-7%) info
Market Cap: $26.556M info
BIOX
May 11, 2026, 5:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.557789
Real-time Price: $0.420 info
Change: -$0.137789 (-25%) info
Market Cap: $26.556M info
BIOX
Apr 28, 2026, 11:23 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.4862
Real-time Price: $0.420 info
Change: -$0.0662 (-14%) info
Market Cap: $26.556M info
BIOX
Apr 28, 2026, 11:11 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.5033
Real-time Price: $0.420 info
Change: -$0.0833 (-17%) info
Market Cap: $26.556M info
BIOX
Mar 24, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.4097
Real-time Price: $0.420 info
Change: +$0.0103 (+3%) info
Market Cap: $26.556M info
BIOX
Mar 17, 2026, 9:16 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.4365
Real-time Price: $0.420 info
Change: -$0.0165 (-4%) info
Market Cap: $26.556M info
BIOX
Mar 13, 2026, 5:23 PM EDT
Filing Type: 6-K
Importance Score:
10
Price at Filing: $0.530
Real-time Price: $0.420 info
Change: -$0.110 (-21%) info
Market Cap: $26.556M info
BIOX
Mar 13, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.5277
Real-time Price: $0.420 info
Change: -$0.1077 (-20%) info
Market Cap: $26.556M info
BIOX
Mar 05, 2026, 4:10 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.557
Real-time Price: $0.420 info
Change: -$0.137 (-25%) info
Market Cap: $26.556M info
BIOX
Feb 05, 2026, 5:49 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.5438
Real-time Price: $0.420 info
Change: -$0.1238 (-23%) info
Market Cap: $26.556M info
BIOX
Jan 21, 2026, 6:19 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.22
Real-time Price: $0.420 info
Change: -$0.800 (-66%) info
Market Cap: $26.556M info
BIOX
Jan 20, 2026, 4:02 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $0.420 info
Change: -$0.880 (-68%) info
Market Cap: $26.556M info